New phase III psoriasis data show rapid, significant skin clearance and convenient administration with Novartis’ secukinumab (AIN457)
Novartis announced (March 22, 2014) results from the pivotal phase III FEATURE and JUNCTURE studies showing secukinumab (AIN457), an interleukin-17A (IL-17A) inhibitor, demonstrated consistent high efficacy when administered with a convenient pre-filled syringe (PFS) or […]